Indications
Pharmacology
Gamma-aminobutyric acid (GAB) is an inhibitory neurotransmitter that may have a basic counterpart in the drug pregabalin (GABA). It is not directly linked to benzodiazepine, GABAA, or GABAB receptors. Pregabalin has a strong affinity for the central nervous system tissues that contain the helper subunit of voltage-gated calcium channels, alpha-2-delta. Pregabalin has a 90% verbal bioavailability that is independent of measures. In persons with normal renal function, it is primarily eliminated from the systemic circulation through renal excretion as an unchanged drug with a median end half-life of 6.3 hours.
Dosage & Administration
Interaction
Pregabalin has no noteworthy interactions with other antiepileptic medicines or oral contraceptives. The effects of ethanol and lorazepam may be amplified by pregabalin.
Contraindications
Patients who have a known hypersensitivity to Pregabalin or any of its components should avoid taking it.
Side Effects
Dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and aberrant thinking are the most common adverse effects.
Pregnancy & Lactation
Pregabalin has a pregnancy category of C. As a result, it should only be taken if the potential benefit outweighs the dangers to the fetus.
Pregabalin, like other medicines, can pass into breast milk, thus it should only be used in nursing mothers if the benefits clearly outweigh the risks.
Precautions & Warnings
Pregabalin withdrawal without tapering might result in insomnia, motion sickness, headaches, and diarrhea. Therefore, rather than stopping suddenly, it should be reduced gradually over a minimum of 1 week. Pregabalin treatment may cause an increase in creatinine kinase. If myopathy is identified or suspected, or if the level of creatinine kinase is noticeably high, it should be stopped right away.
Storage Conditions
Keep away from light and moisture in a cool, dry location (below 30° C). Keep out of children's reach.